Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOther Accumulated ExpensesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Bioregenx (BRGX) Total Debt (2021 - 2025)

Bioregenx has reported Total Debt over the past 5 years, most recently at $1.2 million for Q4 2025.

  • For Q4 2025, Total Debt rose 4.14% year-over-year to $1.2 million; the TTM value through Dec 2025 reached $1.2 million, up 4.14%, while the annual FY2025 figure was $1.2 million, 4.14% up from the prior year.
  • Total Debt for Q4 2025 was $1.2 million at Bioregenx, down from $2.3 million in the prior quarter.
  • Over five years, Total Debt peaked at $2.3 million in Q3 2025 and troughed at $200000.0 in Q4 2021.
  • A 5-year average of $1.1 million and a median of $1.1 million in 2024 define the central range for Total Debt.
  • Biggest five-year swings in Total Debt: changed 0.0% in 2022 and later skyrocketed 875.61% in 2024.
  • Year by year, Total Debt stood at $200000.0 in 2021, then changed by 0.0% to $200000.0 in 2022, then surged by 350.68% to $901362.0 in 2023, then rose by 26.24% to $1.1 million in 2024, then grew by 4.14% to $1.2 million in 2025.
  • Business Quant data shows Total Debt for BRGX at $1.2 million in Q4 2025, $2.3 million in Q3 2025, and $2.1 million in Q2 2025.